GSK Selects Exelixis’ Phase II MET Inhibitor XL880
This article was originally published in The Pink Sheet Daily
Executive Summary
XL880 is first compound to be selected by GSK under collaboration that allows U.K. drug maker to choose three of 12 Exelixis candidates.
You may also be interested in...
Exelixis Hopes To Avoid The Whole Capital Mess By Peddling Its Pipeline
Biotech outlines a post-GSK plan to operate without going to the capital markets while refocusing on internal development.
Exelixis Hopes To Avoid The Whole Capital Mess By Peddling Its Pipeline
Biotech outlines a post-GSK plan to operate without going to the capital markets while refocusing on internal development.
GSK/Exelixis: The End of an Era
Six-year alliance allowed Exelixis to build a pipeline; after gaining $260 million in funding, GSK walks away with rights to only one compound.